Clinical Trial

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-02-17; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2022-04-25
Trial Details
NCT Number NCT05257590
Lead Sponsor TaiRx, Inc.
Conditions Hepatocellular Carcinoma, Advanced Cancer
Enrollment 95 participants
Start Date 2022-05-23
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13